Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 8/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5971061 | 1.00 | PDCD1 (0.62) | PDCD1CD274MAPTFBP1GRM5 | |
| SCHEMBL5970509 | 0.81 | PDCD1 (0.54) | PDCD1CD274MAPTFBP1ALDH1A1 | |
| SCHEMBL7417299 | 0.81 | PDCD1 (0.74) | PDCD1CD274MAPTFBP1GRM5 | |
| SCHEMBL10848993 | 0.79 | PDCD1 (0.71) | PDCD1CD274MAPTFBP1GRM5 | |
| SCHEMBL10375509 | 0.79 | PDCD1 (0.71) | PDCD1CD274MAPTFBP1GRM5 | |
| SCHEMBL5970550 | 0.79 | PDCD1 (0.57) | PDCD1CD274FBP1GRM5CYP1A2 | |
| SCHEMBL5970556 | 0.79 | PDCD1 (0.57) | PDCD1CD274FBP1GRM5CYP1A2 | |
| SCHEMBL21457292 | 0.77 | PDCD1 (1.00) | PDCD1CD274MAPTALDH1A1KMT2A | |
| SCHEMBL21457289 | 0.77 | PDCD1 (1.00) | PDCD1CD274MAPTALDH1A1KMT2A | |
| SCHEMBL5970912 | 0.75 | PDCD1 (0.51) | PDCD1CD274FBP1P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | PDCD1 3406/4885CD274 4342/4885MAPT 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.